Motilal Oswal’s research report on Dr Reddys Labs
Dr. Reddy’s Labs’ (DRRD) 2QFY22 results came in ahead of our estimates, driven by a strong show in Russia, Rest of the World (RoW), Domestic Formulations (DF), and license fee for the sale of US and Canada…

Click here to view the original article.